Cycle view of the study programme

		Bl	Or	Th	Pr	Au	Cr

Information

Professor Ph HUBERT
Analytical chemistry
B36 - 4000 Liege
Phone number: 04/366 43 16
e-mail address: Ph.Hubert@uliege.be

Collegiality

For ULiege: Vincent BIERLAIRE, Bruno BOULANGER, Raphaël DENOOZ, Laurence DENIS, Brigitte EVRARD, Marianne FILLET, Michel FREDERICH, Philippe HUBERT, Roland MARINI, Dominique MARTIN, Bernard PIROTTE, Régis RADERMECKER, Jean-Michel VANDERHOFSTADT, Eric ZIEMONS.
For ULB: Patrick DI STEFANO, François DUFRASNE, Walid EL AZAB, Véronique FONTAINE, Jonathan GOOLE, Anne LENAERS, Hugues MALONNE, Thierry SCHURMANS, Caroline STEVIGNY, Pierre VAN ANTWERPEN, Francis VANDERBIST, Karen VAN MALDEREN, David VERMIJLEN, Zéna WIMANA.
For UCLouvain: Catherine DRUEZ, Laure ELENS, Xavier MARCELIS, François-Xavier MATHY, Jacques POUPAERT, Thierry PRONCE, Joëlle LECLERCQ, Nevin SERBEST, Rita VANBEVER.

Compulsory courses (B1 : 60Cr)

PHIN2004-1	*Active substances*	B1	TA				**6**
	- Substances issues de recherches pharmacochimiques, part a - Bernard PIROTTE		10	-	-		
	- Substances issues de recherches pharmacochimiques, part b - François DUFRASNE		5	-	-		
	- Substances issues des biotechnologies - David VERMIJLEN		15	-	-		
	- Substances d'origine naturelle, part a - Joëlle LECLERCQ		5	-	-		
	- Substances d'origine naturelle, part b - Caroline STEVIGNY		5	-	-		
	- Produits radiopharmaceutiques - Zena WIMANA		10	-	-		
PHIN2008-2	*Clinical viewpoints*	B1	TA				**6**
	- Métabolisme des médicaments et paramètres pharmacocinétiques - FrançoisXavier MATHY		20	-	-		
	- Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - Régis RADERMECKER		15	-	-		
	- Information et pharmacovigilance - Raphaël DENOOZ		10	-	-		
PHIN2013-2	*Quality assurance and pharmaceutical management*	B1	TA				**7**
	- Principles of pharmaceutical management - JeanMichel VAN DER HOFSTADT		10	-	-		
	- Quality assurance, part a : basic concepts and quality assurance organisation - Thierry PRONCE		20	-	-		
	- Quality assurance, part b: Qualification and validation approach and risk analysis - Xavier MARCELIS		7,5	-	-		
	- English applied to the pharmaceutical industry - Jacques POUPAERT, Nevin SERBEST		20	-	-		
	- Pharmaceutical marketing - Vincent BIERLAIRE		7,5	-	-		
PHIN2033-1	*Industrial pharmaceutical technology*	B1	TA				**8**
	- Industrial pharmaceutical microbiology - Véronique FONTAINE		15	-	-		
	- Preformulation and selection of galenical forms - Jonathan GOOLE		15	-	-		
	- Industrial production of galenical forms - Brigitte EVRARD		15	-	-		
	- Industrial production of biomolecules - Rita VANBEVER		15	-	-		
	- Industrial aspects of technological development including packaging - Laurence DENIS		10	-	-		
PHIN2023-1	*Drug analysis*	B1	TA				**7**
	- Methods in pharmaceutical and biopharmaceutical analysis, part a : Detection of (bio)pharmaceutical products - Pierre VAN ANTWERPEN		10	-	-		
	- Methods in pharmaceutical and biopharmaceutical analysis, part b : Preparation and separation of (bio) pharmaceutical products for		10	-	-		

	quality control and pharmacokinetic study - Marianne FILLET - *Methods in pharmaceutical and biopharmaceutical analysis, part c : Validation and qualification of equipment* - Philippe HUBERT, Roland MARINI DJANG'EING'A - *Methods in pharmaceutical and biopharmaceutical analysis, part d : Vibrational spectroscopy* - Eric ZIEMONS - *Statistical methods applied to the pharmaceutical industry* - Laure ELENS - *Experimental planning and "quality by design"* - Bruno BOULANGER		15 5 15 10	- - - -	- - - -		
PHIN2029-2	*Regulation and the medical-social environment* - *Economic aspects of drug development* - Dominique MARTIN - *Legislation and procedures applied to pharmaceutical industry, part a : legislation* - Catherine DRUEZ - *Legislation and procedures applied to pharmaceutical industry, part b : patents and protection* - Patrick DI STEFANO - *Macroeconomic environment and pharmaco-economics* - Hugues MALONNE - *CTD File (Common Technical Document)* - Walid EL AZAB - *Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files* - Karen VAN MALDEREN - *Regulations of preclinical and clinical studies, part b : clinical studies* - Anne LENAERS - *Regulations of preclinical and clinical studies, part c : pediatric studies* - Thierry SCHURMANS - *Specific regulatory issues, part a : medicine and herbal dietary supplement* - Michel FREDERICH - *Specific regulatory issues, part b : Preformulation and galenical development documentation* - Francis VANDERBIST	B1	TA 10 10 5 10 15 15 5 2,5 5 5	 - 5 - - - - - - - -	 - - - - - - - - - -		**8**
PHIN2032-1	*Visits and seminars organised in the pharmaceutical industry* - François DUFRASNE, Marianne FILLET, Joëlle LECLERCQ, Rita VANBEVER - [77,5h Vis.]	B1	TA	-	-	[+]	**3**
MTFE2000-1	*Final work* - François DUFRASNE, Philippe HUBERT, Joëlle LECLERCQ	B1	TA	-	-	-	**15**